Daniel O’Connor has resigned as chief executive of US biotech Advaxis (Nasdaq: ADXS).
The oncology immunotherapy specialist announced the news late on Thursday, sending the company’s share price down by 7.5% in after-hours trading to $6.20.
No reason was given for Mr O’Connor’s departure but the company quoted him as saying: “I am grateful to have had the opportunity to lead Advaxis for the past several years. The company has powerful technology and a strong management team. I have every confidence in their ability to ensure the company’s continued success.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze